Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths, Matthew W. Johnson, Michael A. Carducci, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 12, pp. 1181-1197
Open Access | Times Cited: 1689

Showing 1-25 of 1689 citing articles:

Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 15, pp. 1402-1411
Open Access | Times Cited: 987
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Alan K. Davis, Frederick S. Barrett, Darrick G. May, et al.
JAMA Psychiatry (2020) Vol. 78, Iss. 5, pp. 481-481
Open Access | Times Cited: 924
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
Robin Carhart‐Harris, Karl Friston
Pharmacological Reviews (2019) Vol. 71, Iss. 3, pp. 316-344
Open Access | Times Cited: 770
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Robin Carhart‐Harris, Mark Bolstridge, Camilla Day, et al.
Psychopharmacology (2017) Vol. 235, Iss. 2, pp. 399-408
Open Access | Times Cited: 761
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, et al.
Psychological Medicine (2018) Vol. 49, Iss. 4, pp. 655-663
Open Access | Times Cited: 661
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman, David Nutt, Robin Carhart‐Harris
Frontiers in Pharmacology (2018) Vol. 8
Open Access | Times Cited: 636
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 18, pp. 1637-1648
Open Access | Times Cited: 635
Serotonin and brain function: a tale of two receptors
RL Carhart-Harris, DJ Nutt
Journal of Psychopharmacology (2017) Vol. 31, Iss. 9, pp. 1091-1120
Open Access | Times Cited: 591
Psychedelics and the essential importance of context
Robin Carhart‐Harris, Leor Roseman, Eline Haijen, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 7, pp. 725-731
Closed Access | Times Cited: 504
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Robin Carhart‐Harris, Guy M. Goodwin
Neuropsychopharmacology (2017) Vol. 42, Iss. 11, pp. 2105-2113
Open Access | Times Cited: 500
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Robin Carhart‐Harris, Leor Roseman, Mark Bolstridge, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 464
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin Reiff, Elon E. Richman, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2020) Vol. 177, Iss. 5, pp. 391-410
Closed Access | Times Cited: 446
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression
Rosalind Watts, Camilla Day, Jacob Krzanowski, et al.
Journal of Humanistic Psychology (2017) Vol. 57, Iss. 5, pp. 520-564
Closed Access | Times Cited: 444
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Roland R. Griffiths, Matthew W. Johnson, William A. Richards, et al.
Journal of Psychopharmacology (2017) Vol. 32, Iss. 1, pp. 49-69
Open Access | Times Cited: 419
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, et al.
Pharmacology & Therapeutics (2018) Vol. 197, pp. 83-102
Closed Access | Times Cited: 419
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 10, pp. 953-953
Open Access | Times Cited: 408
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Franz X. Vollenweider, Katrin H. Preller
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 11, pp. 611-624
Closed Access | Times Cited: 405
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
M. Madsen, Patrick M. Fisher, Daniel Burmester, et al.
Neuropsychopharmacology (2019) Vol. 44, Iss. 7, pp. 1328-1334
Open Access | Times Cited: 376
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
Kuglae Kim, Tao Che, Ouliana Panova, et al.
Cell (2020) Vol. 182, Iss. 6, pp. 1574-1588.e19
Open Access | Times Cited: 373
The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
David B. Yaden, Roland R. Griffiths
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 568-572
Open Access | Times Cited: 361
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Ling-Xiao Shao, Clara Liao, Ian Gregg, et al.
Neuron (2021) Vol. 109, Iss. 16, pp. 2535-2544.e4
Open Access | Times Cited: 359
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor
Katrin H. Preller, Joshua B. Burt, Jie Lisa Ji, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 335
Predicting Responses to Psychedelics: A Prospective Study
Eline Haijen, Mendel Kaelen, Leor Roseman, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 317
Psychedelics, Meditation, and Self-Consciousness
Raphaël Millière, Robin Carhart‐Harris, Leor Roseman, et al.
Frontiers in Psychology (2018) Vol. 9
Open Access | Times Cited: 305
Psychedelics as Medicines: An Emerging New Paradigm
DE Nichols, MW Johnson, CD Nichols
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 2, pp. 209-219
Closed Access | Times Cited: 296
Page 1 - Next Page

Scroll to top